Insmed INSM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81.8%+2.1pp | 79.7%+3.2pp | 76.5%+0.8pp | 75.7%-0.8pp | 76.5%+0.1pp | |
| Operating margin | -140.6%+65.0pp | -205.6%+53.3pp | -258.9%-6.5pp | -252.4%+5.0pp | -257.4%-16.0pp | |
| Net margin | -144.4%+66.1pp | -210.5%+54.3pp | -264.8%-5.0pp | -259.8%+6.1pp | -265.9%-14.7pp | |
| EBITDA margin | -138.3%+64.6pp | -202.9%+53.0pp | -255.9%-6.6pp | -249.3%+5.2pp | -254.5%-16.0pp | |
| Free cash flow margin | -112.5%+47.1pp | -159.6%+43.2pp | -202.7%+15.5pp | -218.2%-11.0pp | -207.1%-13.1pp | |
| Returns | ||||||
| Return on equity | -294.5%-45.2pp | -249.3%-83.6pp | -165.7%-5.1pp | -160.5%— | —— | |
| Return on assets | -61%-1.5pp | -59.5%-5.9pp | -53.6%-5.4pp | -48.2%+20.2pp | -68.4%-14.0pp | |
| Return on invested capital | -149.4%-2.8pp | -146.6%-41.8pp | -104.8%+260pp | -365.2%-167pp | -198.3%-60.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.1× | 0.3×+0.1× | 0.2×0.0× | 0.2×-0.1× | 0.3×0.0× | |
| Inventory turnover | 1.3×+0.2× | 1.1×+0.1× | 1×0.0× | 1×0.0× | 1×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.5×+0.6× | 3.8×-0.8× | 4.6×-2.0× | 6.7×+0.8× | 5.9×+0.4× | |
| Quick ratio | 4.1×+0.6× | 3.5×-0.8× | 4.3×-2.0× | 6.3×+0.9× | 5.4×+0.3× | |
| Cash ratio | 1.6×+0.5× | 1.1×+0.3× | 0.8×-3.3× | 4.1×+2.4× | 1.7×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.8×0.0× | 0.8×+0.2× | 0.6×+0.1× | 0.5×-11.1× | 11.5×+7.5× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.2×0.0× | 0.2×-0.4× | 0.6×+0.1× | |
| Interest coverage | -14×+0.9× | -14.9×-1.2× | -13.7×-1.9× | -11.8×-0.3× | -11.5×-1.1× | |
| Per Share | ||||||
| Book value per share | $3.27-11.9% | $3.71-16.8% | $4.47-32.4% | $6.60+1,104% | $0.55-68.5% | |
| Valuation | ||||||
| Market capitalization | $35.25B-5.0% | $37.12B+21.9% | $30.44B+51.3% | $20.12B+45.7% | $13.81B+11.8% | |
| Enterprise value | $35.25B-5.2% | $37.2B+21.2% | $30.68B+58.1% | $19.41B+33.4% | $14.55B+12.4% | |
| Price / sales | 43×-18.2× | 61.2×-6.9× | 68.1×+17.6× | 50.5×+14.3× | 36.2×+2.3× | |
| Price / book | 50×-0.2× | 50.2×+18.0× | 32.2×+16.1× | 16.1×-123× | 139.3×+96.0× | |
| EV / sales | 43×-18.3× | 61.3×-7.3× | 68.6×+19.9× | 48.7×+10.6× | 38.2×+2.6× | |
| Free cash flow yield | -2.6%0.0pp | -2.6%+0.4pp | -3%+1.3pp | -4.3%+1.4pp | -5.7%0.0pp | |
| Earnings yield | -3.4%+0.1pp | -3.4%+0.4pp | -3.9%+1.3pp | -5.1%+2.2pp | -7.3%+0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insmed's profit margins?
- Insmed (INSM) runs a 81.8% gross margin and a -140.6% operating margin, with a -144.4% net margin.
- Where do Insmed's ratios come from?
- Every ratio is computed from Insmed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
